425 related articles for article (PubMed ID: 29584456)
1. Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design.
Pujade-Lauraine E; Fujiwara K; Dychter SS; Devgan G; Monk BJ
Future Oncol; 2018 Sep; 14(21):2103-2113. PubMed ID: 29584456
[TBL] [Abstract][Full Text] [Related]
2. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Disis ML; Taylor MH; Kelly K; Beck JT; Gordon M; Moore KM; Patel MR; Chaves J; Park H; Mita AC; Hamilton EP; Annunziata CM; Grote HJ; von Heydebreck A; Grewal J; Chand V; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):393-401. PubMed ID: 30676622
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 trial of avelumab (anti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial.
Doi T; Iwasa S; Muro K; Satoh T; Hironaka S; Esaki T; Nishina T; Hara H; Machida N; Komatsu Y; Shimada Y; Otsu S; Shimizu S; Watanabe M
Gastric Cancer; 2019 Jul; 22(4):817-827. PubMed ID: 30515672
[TBL] [Abstract][Full Text] [Related]
6. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
7. Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition.
Zhang L; Chen Y; Li F; Bao L; Liu W
Front Immunol; 2019; 10():867. PubMed ID: 31105696
[TBL] [Abstract][Full Text] [Related]
8. Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial.
Park K; Özgüroğlu M; Vansteenkiste J; Spigel D; Yang JCH; Ishii H; Garassino M; de Marinis F; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Xiong H; Bajars M; Ruisi M; Barlesi F
J Thorac Oncol; 2021 Aug; 16(8):1369-1378. PubMed ID: 33845211
[TBL] [Abstract][Full Text] [Related]
9. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Dirix LY; Takacs I; Jerusalem G; Nikolinakos P; Arkenau HT; Forero-Torres A; Boccia R; Lippman ME; Somer R; Smakal M; Emens LA; Hrinczenko B; Edenfield W; Gurtler J; von Heydebreck A; Grote HJ; Chin K; Hamilton EP
Breast Cancer Res Treat; 2018 Feb; 167(3):671-686. PubMed ID: 29063313
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials.
Kelly K; Infante JR; Taylor MH; Patel MR; Wong DJ; Iannotti N; Mehnert JM; Loos AH; Koch H; Speit I; Gulley JL
Cancer; 2018 May; 124(9):2010-2017. PubMed ID: 29469949
[TBL] [Abstract][Full Text] [Related]
11. Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.
Donahue RN; Lepone LM; Grenga I; Jochems C; Fantini M; Madan RA; Heery CR; Gulley JL; Schlom J
J Immunother Cancer; 2017; 5():20. PubMed ID: 28239472
[TBL] [Abstract][Full Text] [Related]
12. Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial.
Keilholz U; Mehnert JM; Bauer S; Bourgeois H; Patel MR; Gravenor D; Nemunaitis JJ; Taylor MH; Wyrwicz L; Lee KW; Kasturi V; Chin K; von Heydebreck A; Gulley JL
J Immunother Cancer; 2019 Jan; 7(1):12. PubMed ID: 30651126
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
Mego M; Svetlovska D; Chovanec M; Rečkova M; Rejlekova K; Obertova J; Palacka P; Sycova-Mila Z; De Giorgi U; Mardiak J
Invest New Drugs; 2019 Aug; 37(4):748-754. PubMed ID: 31152292
[TBL] [Abstract][Full Text] [Related]
14. Which place for avelumab in the management of urothelial carcinoma?
Larroquette M; Gross-Goupil M; Daste A; Robert G; Ravaud A; Domblides C
Expert Opin Biol Ther; 2019 Sep; 19(9):863-870. PubMed ID: 31286802
[No Abstract] [Full Text] [Related]
15. Avelumab and other recent advances in Merkel cell carcinoma.
Bommareddy PK; Kaufman HL
Future Oncol; 2017 Dec; 13(30):2771-2783. PubMed ID: 28976209
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of AEZS-108 (INN: zoptarelin doxorubicin acetate) an LHRH agonist linked to doxorubicin in women with platinum refractory or resistant ovarian cancer expressing LHRH receptors: a multicenter phase II trial of the ago-study group (AGO GYN 5).
Emons G; Gorchev G; Sehouli J; Wimberger P; Stähle A; Hanker L; Hilpert F; Sindermann H; Gründker C; Harter P
Gynecol Oncol; 2014 Jun; 133(3):427-32. PubMed ID: 24713545
[TBL] [Abstract][Full Text] [Related]
17. Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
Bonaca MP; Moslehi JJ; Ledermann JA; Michelon E; Wei C; Moran M; Monk BJ; Pujade-Lauraine E
Oncologist; 2023 Oct; 28(10):e977-e980. PubMed ID: 37665777
[TBL] [Abstract][Full Text] [Related]
18. JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer.
Yu Y; Lee NY
Future Oncol; 2019 Mar; 15(7):687-694. PubMed ID: 30461306
[TBL] [Abstract][Full Text] [Related]
19. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
Planchard D; Yokoi T; McCleod MJ; Fischer JR; Kim YC; Ballas M; Shi K; Soria JC
Clin Lung Cancer; 2016 May; 17(3):232-236.e1. PubMed ID: 27265743
[TBL] [Abstract][Full Text] [Related]
20. Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
D'Angelo SP; Hunger M; Brohl AS; Nghiem P; Bhatia S; Hamid O; Mehnert JM; Terheyden P; Shih KC; Brownell I; Lebbé C; Lewis KD; Linette GP; Milella M; Schlichting M; Hennessy MH; Bharmal M
Cancer Immunol Immunother; 2019 Apr; 68(4):609-618. PubMed ID: 30721341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
